Bristol Myers Squibb announces success of KRAZATI in Phase 3 KRYSTAL-12 study

Bristol Myers Squibb (NYSE: BMY) has reached a pivotal milestone in the treatment of non-small cell lung cancer (NSCLC) with its announcement regarding the KRYSTAL-12 ... Read More